Cambridge-based clinical-stage biopharmaceutical company, Infinity Pharmaceuticals, Inc., solely dedicates itself to providing cancer patients with innovative medications. The company's primary focus revolves around their product candidate, eganelisib (IPI-549). This orally administered immuno-oncology product candidate works to inhibit the enzyme phosphoinositide-3-kinase-gamma and is currently undergoing Phase 2 clinical trials for treating metastatic triple negative breast cancer and urothelial cancer. It's also undergoing Phase 1/1b clinical trials for solid tumors. Infinity Pharmaceuticals has established strategic partnerships with top-tier companies like Intellikine, Inc., Verastem, Inc., PellePharm, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company for various research and development initiatives. The company's foundation dates back to 1995, and they continue to operate and innovate from their headquarters in Cambridge.